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Chemical Biology, and 6Institute for Global Health, Vanderbilt University Medical Center, Nashville, TennesseeABSTRACT The renal outer medullary potassium channel (ROMK, or Kir1.1, encoded by KCNJ1) critically regulates renal
tubule electrolyte and water transport and hence blood volume and pressure. The discovery of loss-of-function mutations in
KCNJ1 underlying renal salt and water wasting and lower blood pressure has sparked interest in developing new classes of anti-
hypertensive diuretics targeting ROMK. The recent development of nanomolar-affinity small-molecule inhibitors of ROMK cre-
ates opportunities for exploring the chemical and physical basis of ligand-channel interactions required for selective ROMK
inhibition. We previously reported that the bis-nitro-phenyl ROMK inhibitor VU591 exhibits voltage-dependent knock-off at hy-
perpolarizing potentials, suggesting that the binding site is located within the ion-conduction pore. In this study, comparative mo-
lecular modeling and in silico ligand docking were used to interrogate the full-length ROMK pore for energetically favorable
VU591 binding sites. Cluster analysis of 2498 low-energy poses resulting from 9900 Monte Carlo docking trajectories on
each of 10 conformationally distinct ROMK comparative homology models identified two putative binding sites in the transmem-
brane pore that were subsequently tested for a role in VU591-dependent inhibition using site-directed mutagenesis and patch-
clamp electrophysiology. Introduction of mutations into the lower site had no effect on the sensitivity of the channel to VU591.
In contrast, mutations of Val168 or Asn171 in the upper site, which are unique to ROMK within the Kir channel family, led to
a dramatic reduction in VU591 sensitivity. This study highlights the utility of computational modeling for defining ligand-
ROMK interactions and proposes a mechanism for inhibition of ROMK.INTRODUCTIONThe renal outer medullary Kþ (ROMK, Kir1.1) channel is
a product of the gene KCNJ1 and founding member of the
inward rectifier Kþ (Kir) channel family (1,2). ROMK is
expressed in the thick ascending limb of Henle’s loop and
mineralocorticoid-sensitive cortical collecting duct of the
kidney tubule, where it critically regulates transepithelial
Naþ and osmotically coupled H2O reabsorption and K
þ
excretion (3,4). Greger and Schlatter (1981) first demon-
strated that NaCl reabsorption in the mammalian TAL is
coupled to a Ba2þ-inhibitable Kþ conductance in the
luminal membrane. Using isolated-perfused tubule seg-
ments, they found that perfusing the tubule lumen with
Ba2þ-containing or Kþ-free solutions reduced the transepi-
thelial short-circuit current (Isc) by ~36%. Perfusion with
a Kþ-free, Ba2þ-containing solution virtually eliminated
the Isc (5). The investigators subsequently found that the
luminal membrane is almost exclusively Kþ-conductive
and concluded that this conductance is responsible for the
recycling of Kþ ions across the luminal membrane, which
in turn provides substrate Kþ ions needed for the activity
of the Naþ-Kþ-2Cl cotransporter (6).Submitted November 5, 2014, and accepted for publication January 23,
2015.
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0006-3495/15/03/1094/10 $2.00Patch-clamp recordings of the luminal membrane re-
vealed at least two distinct populations of Ba2þ-inhibitable
Kþ channels that could contribute to Kþ recycling in the
TAL: an intermediate-conductance Kþ channel of ~70 pS
and a small-conductance channel of ~30 pS. With the ex-
ception of their sensitivity to Ba2þ, the two channels differ
dramatically in their pharmacological properties. For
example, the ~70 pS channel is inhibited by quinidine, tet-
raethylammonium ions, and Ca2þ, whereas the 30 pS chan-
nel is largely insensitive to these blockers. In contrast, the
KATP channel antagonist glyburide (glibenclamide) inhibits
the ~30 pS channel, but not the ~70 pS channel. This latter
point is of interest because it was shown that glyburide dose-
dependently increases urinary Naþ excretion in rats without
affecting Kþ excretion (7). Similar results were subse-
quently reported for the structurally unrelated KATP channel
inhibitor, U37883A (8). Taken together, these data suggest
that pharmacological inhibition of the ~30 pS channel spe-
cifically, without inhibiting the 70 pS channel, is sufficient
to induce diuresis in rodents.
Indeed, a growing body of genetic evidence supports the
notion that ROMK represents a new diuretic target in hu-
mans. Autosomal-recessive loss-of-function (LOF) muta-
tions in KCNJ1 give rise to antenatal (type II) Bartter
syndrome, a life threatening renal tubulopathy presentinghttp://dx.doi.org/10.1016/j.bpj.2015.01.022
ROMK Inhibitor Binding Site 1095with excessive urination, low to normal blood pressure,
metabolic alkalosis, and hypokalemia (9–11). The observa-
tion that antenatal Bartter syndrome patients exhibit urinary
Kþ wasting seems contradictory, given that ROMK consti-
tutes an important pathway for distal Kþ secretion. How-
ever, studies of KCNJ1/ mice revealed an important
role of flow-stimulated big-conductance calcium-activated
Kþ (BK) channels in mediating Kþ secretion in the absence
of ROMK (12,13). Interestingly, heterozygous carriers of
KCNJ1 LOF mutations have lower blood pressure and
are protected from stroke, but do not exhibit the clinical
features of Bartter syndrome (14). These observations pro-
vided strong human genetic evidence for ROMK as a novel
diuretic target for the treatment of hypertension.
The small-molecule pharmacology of ROMK remained
largely undeveloped for more than 15 years after ROMK
was cloned (1,2). To our knowledge, the first publically dis-
closed inhibitor, termed VU590 (7,13-bis[(4-nitrophenyl)
methyl]-1,4,10-trioxa-7,13-diazacyclopentadecane dihydro-
chloride), was discovered by our group in a high-throughput
screen (HTS) of ~225,000 compounds from the Molecular
Libraries Screening Center Network (MLSCN) library.
VU590 inhibits ROMK with a 50% inhibitory concentration
(IC50) of ~220 nM but suffers from poor selectivity due to
weak activity toward Kir7.1 (IC50 8 mM) (15). The second in-
hibitor from the MLSCN probe development campaign was
VU591 (6-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)methox-
ymethyl]-1H-benzimidazole hydrochloride) which, like
VU590, contains two nitro (NOO) groups flanking a nitro-
gen- and oxygen-rich linker (see Fig. 2 A). VU591 inhibits
ROMKwith a 240 nM IC50, is active on native ROMK chan-
nels in isolated-perfused collecting ducts, and is selective
for ROMK over >70 potential off-targets, including Kir7.1
(16).
The recent development of potent and highly selective
small-molecule ROMK inhibitors by our group and Merck
Research Laboratories (17,18) has created unprecedented
opportunities not only for probing the druggability of
ROMK, but also for understanding the chemical and phys-
ical interactions that underlie high-affinity ligand interac-
tions with these important channels. Inward rectifier Kþ
channels are tetramers of identical (homotetramers) or
similar (heterotetramers) subunits. Each subunit contains
two membrane-spanning domains flanking a reentrant
pore loop and a cytoplasmic domain comprised of intracel-
lular amino- and carboxyl-termini. Rectification, or the pro-
pensity to pass inward current more readily than outward
current, is due to pore block by intracellular polyvalent cat-
ions (e.g., Mg2þ and polyamines) interacting with nega-
tively charged amino acid side chains lining the channel
pore. ROMK is a homotetramer that exhibits weak rectifica-
tion compared to the classical strong rectifier Kir2.1. In
ROMK, several negatively charged rectification residues
are replaced with uncharged amino acids that coordinate
pore blockers less strongly.A detailed understanding of how small-molecule inhibi-
tors participate in high-affinity ligand interactions with
ROMK will be valuable for rationalizing future efforts at
drug design. Although the x-ray crystal structure of
ROMK has not been determined, there are several closely-
related channels of known structure, making it possible to
develop a comparative model of ROMK. In this study, we
generate such a model and use it to perform in silico docking
calculations guided by concurrent electrophysiology exper-
iments to arrive at a physical model for inhibition of ROMK
by VU591.MATERIALS AND METHODS
Construction of comparative models of ROMK1
An ensemble of 10 comparative ROMK models was constructed in distinct
conformations to simulate receptor flexibility for the docking studies
(Fig. S1 in the Supporting Material). The experimental structures used as
model templates, 3JYC (Kir2.2), 3SPG (Kir2.2), 3SPH (Kir2.2), 3SPI
(Kir2.2), 3SPJ (Kir2.2), 3SYA (Kir3.2), 3SYC (Kir3.2), 3SYO (Kir3.2),
3SYP (Kir3.2), and 3SYQ (Kir3.2) (19–21), were obtained from the Protein
Data Bank (PDB). The sequence of these 10 channels was aligned with the
sequence of ROMK using ClustalW (22). Sequence identity ranges from
23% to 49%. From this multiple sequence alignment, all-atom comparative
models were generated using Modeler v.9.10 (23). These initial models
were refined using the Relax application in Rosetta v.3.2 (24) with a modi-
fied energy potential to mimic the membrane environment (25,26). Trans-
membrane residue definitions for input to Rosetta were derived from the
Octopus webserver (27) and confirmed visually. The lowest-energy model
from each template was selected out of 1000 refined models generated. The
10 resulting homology models were then used as input for the subsequent
ligand-docking calculations. Further details and command lines are pro-
vided below, and as a protocol capture (http://structbio.vanderbilt.edu/
~sheehajh/denton/swale_protocol_capture.tgz) as part of the Supporting
Material.In silico docking of VU591
RosettaLigand (28) docking was used to predict the lowest-energy binding
mode of VU591 in ROMK. To account for ligand flexibility, 200 low-en-
ergy conformations of VU591 were generated using the systematic confor-
mational search tool in Molecular Operating Environment (MOE) 2013.08
(Chemical Computing Group, Montreal, Quebec, Canada). Rotation and
flexibility about the central ether oxygen and proximal carbons were
permitted, but the flanking nitro groups on VU591 required additional re-
straints in MOE to maintain coplanarity with the aromatic ring systems.
The ligand ensemble was docked 9900 times into each of the 10 ROMK
models. To ensure complete sampling, the ligands were manually placed
in the upper, middle, or lower regions of the ROMK channel pore
(Fig. 1, blue poses) before initiating the random search for low-energy bind-
ing poses. The ligand was allowed to move up to 5 A˚ per step and
completely reorient. VU591 was docked into the ROMK models a total
of 99,000 times. Fig. 1 (middle image) demonstrates that the entire channel
pore was sampled (red). All details of the Rosetta command lines and op-
tions used are included in the Supporting Material.Clustering of low-energy docking poses of VU591
The 1000 lowest-energy docking poses from each template were pooled, for
a total of 10,000 poses for further analysis. The lowest predicted binding
energy (DDG) observed was 16 Rosetta energy units (REUs). BecauseBiophysical Journal 108(5) 1094–1103
Model Construction
An ensemble of 10 models 
of ROMK in distinct 
conformations was built 
from template crystal  
structures of Kir 2.2 and 3.2
Docking
99,000 trials of 200 low-
energy conformations of 
VU591 were run from 3 
starting positions in the 
conduction channel.
Refinement
The energetically best 2498 
poses were clustered by 
RMSD. Predicted contact 
residues were tested by 
mutagenesis and 
electrophysiology. The 
model most consistent with 
the data was selected. 
FIGURE 1 Overview of docking procedure. The flowchart shows the
three parts of the process. (Top) Ten comparative models of ROMK were
built using crystal structures of Kir2.2 and Kir3.2 as templates. This
ensemble of models was used to represent some of the conformational di-
versity in ROMK, which can be seen clearly when the models are overlaid.
(Middle) RosettaLigand was used to predict binding locations of the inhib-
itor. One model is shown in gray, using cutaway mode to expose the con-
duction channel. Three starting positions for VU591 (blue) were used to
sample the entire interior of the channel. Red spheres are used to show
the extent of sampling (only 300 out of 99,000 placements are shown, for
clarity). An ensemble of 200 low-energy conformations was also used for
the inhibitor, to account for flexibility in binding. (Bottom) The lowest-en-
ergy binding predictions were refined using clustering by similarity and
ranking by score. Two of the best predictions are shown as colored spheres
in the context of the complete protein shown in gray outline. To see this
figure in color, go online.
1096 Swale et al.we docked into comparative models, we expect that some inaccuracies in
the models will result in inaccurate energy readout. Therefore, we consid-
ered not just the lowest-scoring binding pose, but all 2498 poses that
displayed a DDG >10 REUs. To analyze the conformational space, we
performed hierarchical clustering analysis (29). The clustering protocol
used a similarity cutoff of root mean-square deviation 4 A˚ between
two ligand poses. Further, it was adapted to take advantage of the fourfoldBiophysical Journal 108(5) 1094–1103symmetry of the channel by combining symmetry-related clusters. This
increased the cluster sizes substantially, thereby reducing the number of
clusters that need to be considered, and increased the size differential be-
tween the largest and all other clusters (Fig. S2 and Table S1). The best-
scoring ligand poses from the largest four clusters were visually inspected.
Clustering was performed using the Biological and Chemical Library
(BCL) (30) software suite from the Meiler Lab. Molecular structure images
were produced using PyMOL [The PyMOL Molecular Graphics System,
Version 1.5.0.4 Schro¨dinger, LLC.] and UCSF Chimera (31).Heterologous ROMK1 expression in HEK-293T
cells
The rat ROMK1 open reading frame (ORF) ligated into pcDNA3.1 was
provided by Dr. Chun Jiang, (Georgia State University, Atlanta, GA).
Site-directed mutagenesis was performed using a QuickChange II kit (Stra-
tagene, La Jolla, CA) and fully sequenced to ensure that only the intended
codon change was incorporated into the ROMK1 ORF. Alanine-scanning
mutagenesis was used for most mutations. Given the close proximity of
C175 to N171 (which is required for inhibition by VU591), C175 was
mutated to alanine, threonine, and isoleucine to more fully explore its po-
tential role in VU591 sensitivity. Isoleucine 182 was mutated to methionine
(which is found in Kir2.1 at the equivalent position) to determine if a methi-
onine accounts for the lack of VU591 sensitivity in Kir2.1. HEK-293T cells
(American Type Culture Collection; Manassas, VA) were transiently co-
transfected with pcDNA3.1-ROMK1 and pcDNA3.1-EGFP (transfection
marker) using Lipofectamine LTX plus (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s instructions.Patch-clamp electrophysiology
Patch-clamp experiments were performed 24 h posttransfection, essentially
as described previously (15,16). Briefly, the cells were rinsed with divalent-
free Hank’s balanced salt solution (145 mM NaCl, 5 mM KCl, 4 mM
NaHCO3, 0.3 mM Na2HPO4, 0.3 mM KH2PO4, and 5.6 mM D-glucose,
pH 7.4, 290 mOsmol/kg of water), dissociated by brief (~60 s) exposure
to 0.25% trypsin containing 1 mM EDTA, plated on poly-L-lysine-coated
round glass coverslips, and allowed to recover at 37C in a 5% CO2 incu-
bator for at least 1 h before experiments. The coverslips were transferred to
a small-volume perfusion chamber (Warner Instruments, Hamden, CT) and
mounted on the stage of a Nikon Eclipse TE2000-U inverted microscope
(Nikon, Tokyo, Japan). Patch electrode resistances ranged from 3 to 5
MU when filled with an intracellular solution of (in mM) 135 KCl, 2
MgCl2, 1 EGTA, 10 HEPES-free acid, and 2 Na2ATP (Roche Diagnostics,
Indianapolis, IN), pH 7.2, 275 mOsmol/kg water. The standard bath solu-
tion contained (in mM) 135 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 5 glucose,
and 10 HEPES-free acid, pH 7.4.
Whole-cell currents were recorded under voltage-clamp conditions
using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA).
Cells were maintained at a holding potential of 75 mV and stepped
every 5 s to 120 mV for 200 ms before ramping to 120 mV at a rate of
1.2 mV/ms. Data were collected at 5 kHz and filtered at 1 kHz. Data acqui-
sition and analysis were performed using pClamp 9.2 software (Molecular
Devices).VU591 preparation
VU591 powder was purchased from Sigma-Aldrich (St. Louis, MO), dis-
solved in anhydrous dimethyl sulfoxide up to 100 mM, and diluted in
bath solution each day before use. For Kir2.1 studies, inhibitor solutions
(50 mM and 100 mM) were made fresh before each recording to reduce
the potential for precipitation of VU591 out of the bath solution.
Final DMSO concentration used in experiments was <0.1% (v/v). Both
ROMK Inhibitor Binding Site 1097recordings were terminated after steady state was reached by applying
2 mM barium (Ba2þ) to allow measurement of residual leak current. Cells
exhibiting <90% block by Ba2þ were excluded from analysis.Statistical analyses
Wild-type and mutagenized ROMK1 channels were initially assayed for
sensitivity to 300 nM VU591. The mean current amplitude recorded over
five successive steps to 120 mV in control or experimental solutions
were compared using a two-tailed, unpaired t-test, with statistical signifi-
cance defined at P < 0.05 (GraphPad InStat, GraphPad Software, San
Diego, CA). IC50 values were determined by fitting the Hill equation to con-
centration-response curves (CRCs) using variable-slope, unconstrained,
nonlinear regression analyses performed with GraphPad Prism.A
B
V168 N171
FIGURE 2 In silico docking of VU591 into a model of ROMK (A)
Chemical structure of VU591. (B) Final binding pose. The model most
consistent with the mutagenesis and electrophysiology data is shown in
detail. The inhibitor VU591 is shown as magenta sticks, and ROMK is
shown in blue cartoon, with neighboring side chains depicted as sticks. In
addition, nitrogen atoms are colored blue, oxygen red, and sulfur yellow.
Two specific residues discussed in the text, V168 and N171, are highlighted
in cyan. To see this figure in color, go online.RESULTS
Comparative molecular modeling and docking
identify putative VU591 binding pockets
VU591 exhibits voltage-dependent knock-off at hyperpola-
rizing voltages, leading us to postulate that the binding site
is locatedwithin the ion conduction pathway (16). In an effort
to test this hypothesis and elucidate the mechanism of action
ofVU591, we used a coupled strategy ofmolecularmodeling
and docking for hypothesis generation, and site-directed
mutagenesis and electrophysiology to test, refine, and vali-
date the models (Fig. 1). A challenge in the application of
protein-ligand docking is the computational expense of
incorporating flexibility of both the ligand and the protein.
This challenge was addressed by using an ensemble-docking
approach to simulate the flexibility of each partner. An
ensemble of 10 conformations of ROMK was constructed
by selecting 10 template structures reflecting Kir3.2 and
Kir2.2 in the presence or absence of different ligands, ions,
and functionally important mutations (19–21) (Fig. S1).
The flexibility of VU591 was simulated in a similar way, us-
ing 200 low-energy conformers as input to the docking calcu-
lation. To ensure complete sampling of the entire length of
the ROMK1 channel (Fig. 1), which extends >80 A˚ from
the extracellular to the intracellular extremity, VU591 was
manually placed at three different starting positions at the
outset of the docking simulations (Fig. 1).
RosettaLigand uses a statistically-derived potential to
score each docking pose according to its predicted energy
(28). In theory, the lowest-energy result should identify
the native binding mode. However, because the energy func-
tion is an imperfect approximation based on physics- and
knowledge-based terms, because we dock into comparative
models with an unknown amount of intrinsic inaccuracy,
and because the sampling density is finite, the predicted en-
ergy score is insufficient to discriminate among binding
poses by itself. This limitation can be addressed by clus-
tering the resulting docking poses according to a similarity
metric, in this case the root mean-square deviation between
poses. Previous work has shown that the depth of the
native energy well correlates with its width, and as a result,relatively more low-energy models tend to accumulate near
the native conformation (32). Our clustering strategy took
into account the fourfold symmetry of the channel, and
achieved significant discriminatory power (Fig. S2 and Ta-
ble S1). The selection of top binding poses was thus a com-
bination of cluster size and low energy. The two largest
clusters stood out by sizes and predicted binding energy.Binding pose
The largest clusters of low-energy binding poses were found
16 A˚ below the selectivity filter (middle; 351 poses) and 6.5 A˚
below the selectivity filter (upper; 109 poses), with additional
smaller clusters as far as 42 A˚ away from the selectivity filter
(lower). Representatives of the upper and middle binding
poses are shown inFig. 1. The upper binding pocket is located
in the ion conduction channel, between the selectivity filter
and the inner helix gate. The ligand VU591 adopts a V-
shaped, or partially folded conformation within the cavity
and displays remarkable shape complementarity with the
cup-shaped pocket. As shown in Fig. 2B, VU591 is predicted
to contact backbone and side-chain atoms of inner helix res-
idues 167–184. This is a surface of mixed hydrophobic and
hydrophilic character. Without additional experimental dis-
tance restraints, the prediction of specific atom-atomcontacts
based on only the lowest-energy result would be overlyBiophysical Journal 108(5) 1094–1103
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performed by combining contact statistics from all members
of each cluster (see Supporting Material for details). The
reasoning is that we have more confidence in ligand-residue
contacts that are found in more of the predicted binding con-
formations. This analysis identified pore-lining residues in
ROMK including N171 and V168, in proximity to the nitro
group of VU591. The compound binds to the surfaces of
two adjacent subunits of the ROMK tetramer simultaneously.
The second binding pocket is located 10 A˚ below the upper
site but still above the intracellular vestibule, and it is slightly
larger in diameter, allowing the ligand to adopt a more
extended conformation. The list of contact residues included
some in the gate and flexible loop regions, but none of these
correlated well with the mutagenesis data (see below) and
were not further pursued.
The best 2498 docking results were found to be distributed
among the H,M,L cavities differently, according to the
conformation of the template fromwhich themodel was built
(Table S2). This is consistent with the idea that the state of the
protein affects both the binding affinity and location of the
probe. It is noteworthy that the diameter of the selectivity fil-
ter is too narrow to allow passage of VU591 from the extra-
cellular side. In models that were built on closed templates,
the conduction channel from the cytoplasmic side of the
pore to the binding site is also too narrow. However, in the
models built in the open conformation (templated on, e.g.,
PDB 3SYQ, which is Kir3.2 with PIP2 bound, and the acti-
vating mutation R201A), it is wide enough for the ligand to
reach the binding site.
To experimentally validate the docking predictions, resi-
dues were prioritized for site-directed mutagenesis using the
likelihood analysis mentioned above. Briefly, residues in
contact with the probe (within 4 A˚ of a ligand atom) were
identified in each of the 10 lowest-energy conformations
of each cluster, and the relative frequency of the contacts
summed over all conformations was used to rank the contact
residues in the putative binding pocket for experimental
testing (for greater detail, see the link to protocol capture
in Materials and Methods).Functional analysis of the putative VU591 binding
pockets in ROMK1
Patch-clamp electrophysiology and site-directed mutagen-
esis were used to test whether residues populating the middle
and upper binding sites identified in docking simulations
contribute to ROMK sensitivity to VU591. As shown in
Fig. 3, B andC, superfusion of cells with 10 mMVU591com-
pletely inhibited ROMK1 current, and the inhibited current
was indistinguishable from the current trace after the applica-
tion of the nonspecific Kir channel inhibitor, barium. The re-
sidual outward current observed in the presence of VU591 is
carried by endogenous Kv currents expressed in HEK293
cells, as VU591 has no effect on this current (16). SomeBiophysical Journal 108(5) 1094–1103ROMK1 mutants (specifically, T304A and N171D/E/Q)
failed to express channel activity that could be distinguished
from the endogenous inward rectifier current expressed in
HEK293 cells. To circumvent this problem, the loss-of-func-
tion mutations were introduced into ROMK1 carrying a mu-
tation of lysine 80 tomethionine (K80M).We and others have
shown that the K80M mutation can rescue the function
of some ROMK1 mutants, presumably by stabilizing the
helix-bundle crossing gate in the open state (33,34). It is
important to note that the IC50 values for VU591 were indis-
tinguishable between ROMK-wild-type (IC50 297 nM) and
ROMK-K80M (IC50 307 nM) (Fig. 3 G).
The binding-site mutants were screened at a concentra-
tion of 300 nM VU591, which is close to the IC50 for the in-
hibitor. As shown in Fig. 4 E, mutating the top-scoring
residues within the middle site, either alone (S183A,
T304A/K80M, and S305A) or in combination (S183A/
S305A), had no effect on VU591 sensitivity compared to
wild-type ROMK1, which was inhibited by 49 5 2.0%
(n¼ 25). We therefore assessed residues in the predicted up-
per binding site, as well as those populating the intervening
region of the pore. S172A, C175A, C175I, C175T, and
I182M were without effect, but the I178A mutation caused
a small (~11%), but significant (P < 0.05), increase in
VU591 sensitivity. L179A and A180L failed to generate
measureable currents in wild-type ROMK1 or the K80M
mutant (data not shown).
Mutation of two residues in the upper site led to striking
changes in the VU591 sensitivity of ROMK1. In single-dose
experiments, 300 nM VU591 inhibited ROMK1-V168A
by only 135 1.8% (n ¼ 10). Representative current traces
of ROMK1, K80M, V168A, and N171D-K80M mutants
exposed to 300 nM are shown in Fig. 4, A–D. CRCs revealed
an approximate fivefold rightward shift in the IC50 of
V168A (IC50 1612 nM) compared to the wild-type channel
(IC50 297 nM). Mutation of V168 to C or L led to IC50
values of 1178 nM and >50 mM, respectively (Fig. 5 A).
Asparagine 171 (N171) of ROMK1 comprises the so-
called rectification controller and corresponds to aspartate
172 (D172) in the classical inward rectifier Kir2.1. Because
Kir2.1 is insensitive to VU591 (16), and given the proximity
and importance of V168 in VU591 sensitivity, we assessed
whether mutation of N171 to D (D172) affects ROMK
sensitivity to VU591. However, ROMK1-N171D carried
no measurable current, prompting us to examine the muta-
tion in the K80M background. Whereas 300 nM VU591 in-
hibited K80M by 48 5 1.6% (n ¼ 10), which was not
statistically different (P > 0.05) from wild-type ROMK1
(Fig. 4 E), the N171D mutation abolished channel sensi-
tivity to this concentration of VU591 (Fig. 4, D and E).
IC50 values for N171D (or N171E) could not be reliably
determined, because <5% inhibition was observed at a
concentration of 50 mM VU591 (Fig. 5 B). Introduction of
the polar uncharged residue glutamine at position 171
(N171Q/K80M) resulted in a 5.5-fold loss in channel
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FIGURE 3 Inhibition of ROMK-WTand ROMK-K80M by VU591. (A–E) Voltage-clamp protocol (A) used to evoke ROMK-WTand ROMK-K80M cur-
rents (B and E, respectively). ROMK-WTactivity was recorded in control buffer (B), in the presence of 10 mMVU591 (C), and in the presence of 2 mMBa2þ
(D). (F) Representative time course of ROMK-K80M inhibition by 10 mMVU591 and by 2 mM Ba2þ. (G) CRC for VU591-dependent inhibition of ROMK-
WT and ROMK-K80M. Data represent the mean 5 SE steady-state inhibition by the indicated concentration of VU591 (n ¼ 5–15). The IC50 values for
ROMK-WT and ROMK-K80M derived from Hill fits to the data are 297 nM and 307 nM, respectively.
ROMK Inhibitor Binding Site 1099sensitivity to VU591 (IC50 1692 nM) compared to ROMK1-
K80M controls (307 nM). Interestingly, the double mutation
V168A/N171Q right-shifted the CRC by 9.5-fold (IC50
2926 nM, 95% CI, 2264–3782; Hill slope, 1.9; r2 ¼ 0.92)
compared to K80M (Fig. 5 C), suggesting that both residues
contribute to VU591-dependent block independently. To in-
crease confidence in the binding site prediction, N171 was
mutated to D in the ROMK model. This in silico mutagen-
esis resulted in a significant (P ¼ 1.89) decrease in the
predicted VU591 binding energy from 14.1 REUs to
11.0 REUs, in agreement with results from patch-clamp
experiments.Reverse-engineering a VU591 binding site into
Kir2.1
To further assess the role of V168 and N171 in the mecha-
nism of ROMK inhibition, we attempted to reverse-engineerVU591 sensitivity by mutating corresponding amino acids,
C169V and D172N, respectively, in Kir2.1. Representative
I-V plots for Kir2.1-WT and Kir2.1-C169V/D172N are
shown in Fig. 6, A and B. As reported previously (16), the
wild-type channel is largely insensitive to VU591 (2 5
1.5% and 9.6 5 1.4% by 50 mM and 100 mM VU591,
respectively; n ¼ 5 each). However, the D172N mutation
increased Kir2.1 sensitivity to VU591 by approximately
threefold (i.e., 6.8 5 1.1% and 22.6 5 3.2% inhibition
at 50 mM and 100 mM VU591, respectively), which was
statistically (P < 0.05) different from that observed for
wild-type Kir2.1 (Fig. 6 C). Although mutation of Kir2.1-
C169 to valine (i.e., Kir2.1-C169V), which corresponds to
ROMK1-V168, did not significantly (P > 0.05) increase
the sensitivity of the channel to VU591 as compared to
Kir2.1-D172N, the double mutant was inhibited by 9 5
1.3% and 28 5 2.8% by 50 mM and 100 mM VU591,
respectively (n¼ 5 each). Taken together, these data supportBiophysical Journal 108(5) 1094–1103
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1100 Swale et al.the conclusion that the VU591 binding site in ROMK1 in-
cludes V168 and N171.DISCUSSION
The molecular pharmacology of the inward rectifier family
has remained underdeveloped since the founding member,
ROMK, was cloned more than 20 years ago (1,2). To
date, nanomolar-affinity antagonists have been developed
for ROMK, Kir2.1, and KATP (Kir6.x/SURx). Potent and
selective KATP channel inhibitors (glibenclamide, tolbuta-
mide) as well as openers (diazoxide, pinacidil) have been
used clinically for decades to treat disorders of insulin
and glucose homeostasis (35). These compounds interact
with high-affinity binding sites located on regulatory SUR
subunits to induce conformational changes that open or
close the Kir6.x channel pore (36,37). Although there is-8 -7 -6 -5 -4
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Biophysical Journal 108(5) 1094–1103some evidence that SUR2B interacts with ROMK and con-
fers weak sensitivity to glibenclamide (38,39), others have
proposed that ROMK is intrinsically sensitive to the inhib-
itor (40).
The small-molecule pharmacology of the Kir family is
dominated by drugs mostly directed toward cardiac and
neurological targets but that also act directly on Kir chan-
nels at higher doses (for review, see Bhave et al. (41) and
Swale et al. (42). For example, the tricyclic antidepressant
nortriptyline and selective serotonin reuptake inhibitor
fluoxetine inhibit Kir4.1 with IC50 values of 28 mM and
15 mM, respectively. Furutani et al. (43) found that mutation
of E158, which corresponds to N171 in ROMK, weakened
inhibition of Kir4.1 by these drugs. Mutation of ROMK-
N171 to glutamine (N171Q) had no effect on channel
pharmacology, whereas ROMK carrying N171E or N171D
mutations exhibits enhanced sensitivity to both blockers.-8 -7 -6 -5 -4
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ROMK Inhibitor Binding Site 1101Similarly, the Kir2.x-selective inhibitor ML133 also re-
quires a negatively charged residue at this position (44),
which is occupied by an aspartate residue (i.e., D172) in
Kir2.1 (44). Mutation of D172 to asparagine (D172N) in
Kir2.1 leads to a nearly eightfold loss of ML133 potency.
In contrast, introduction of a single N171D mutation in
ROMK is sufficient to confer ML133 sensitivity to the
channel.
In this study, we found that introduction of a negatively
charged residue (E or D) at position N171 in ROMK, which
corresponds to Kir4.1-E158 and Kir2.1-D172, obliterates
the sensitivity of the channel to VU591. Robertson and col-
leagues proposed that the introduction or neutralization of
charged residues in the Kir channel pore can influence the
electrostatic potential along the pore, and thus interactions
with Kþ ions as well as charged pore blockers, such as
Mg2þ, as far as 40 A˚ away (45). It is therefore conceivable
that the N171D or N171E mutations disrupt interactions of
VU591 with a binding site some distance away from the
mutation site. We propose that the VU591 binding site is
localized near N171 for the following reasons. First,
in silico docking simulations identified an energetically
favorable interaction between VU591 and N171. Second,
extending the side-chain length by two methyl groups at
position 171 without introducing a charge at this site, led
to a ~5.5-fold loss of VU591 sensitivity in the ROMK-
N171Q mutant. Third, introduction of an asparagine residue
into Kir2.1 at position confers VU591 sensitivity to this
channel. Fourth, neutral mutations of the adjacent pore-lin-
ing residue, V168, also affect channel block. Substitution
of the smaller hydrophobic residues alanine (V168A) or
cysteine (V168C) produced ~5.4- and ~4-fold losses in
potency, respectively. Interestingly, lengthening the side
chain by only one methyl group with a V168L mutation
virtually abolished sensitivity to VU591. Finally, the double
mutation V168A/N171Q produced a greater loss in VU591
sensitivity than did the N171Q mutation alone. These results
are consistent with our computational modeling resultssuggesting that VU591 is capable of interacting with both
residues simultaneously.
It is also conceivable that mutations of V168 or N171
alter the secondary and tertiary structures of ROMK and
consequently the binding site for VU591 elsewhere in the
channel pore. However, even conservative substitutions
such as V168L and N171Q led to striking changes in chan-
nel pharmacology. Furthermore, no other mutations in the
pore reduced sensitivity to VU591, indicating that the ef-
fect is specific to V168 and N171. Rodriguez-Menchaca
found that mutation of residues throughout the mem-
brane-spanning pore, including D172 (equivalent to
ROMK-N171) and C169 (equivalent to ROMK-C168),
had no effect on the chloroquine binding site located in
the cytoplasmic domain of the channel (46). Finally, among
six members of the inward rectifier family tested for sensi-
tivity to the VU591, the only two channels inhibited were
ROMK (IC50 ~290 nM) and Kir6.2/SUR1 (IC50 >50 mM)
(16). An alignment of the primary sequences of the sub-
units reveals that Kir6.2 is the only subunit that contains
an asparagine residue at the position equivalent to that of
ROMK-N171. Kir6.2 contains a methionine residue in the
position corresponding to ROMK-V168. Taken together,
these data support the notion that residues V168 and
N171 of ROMK contribute directly to the binding site for
VU591.
Results from our molecular docking studies may provide
an explanation for why VU591 is ~30-fold more potent than
its precursor inhibitor 1,3-bis(5-nitro-1H-benzo[d]imidazol-
2-yl)propane BNBI (16). The only difference between the
VU591 and BNBI chemical structures is the presence of
an ether oxygen in the linker region of VU591 (Fig. 7)
(16). In a previous study, we postulated that the oxygen
addition improves the potency of VU591 by increasing the
electron donor potential (and hydrogen-bond acceptor po-
tential) of the ether linker and thereby stabilizes ligand inter-
actions with a polar portion of the ROMK channel pore.
Although this may also play a role in determining theBiophysical Journal 108(5) 1094–1103
FIGURE 7 Chemical structures of BNBI, VU591, and Compound A.
1102 Swale et al.potency of VU591, the modeling results offer another poten-
tial explanation. The ROMK channel pore near N171 and
V168 is too narrow to accommodate the fully extended
small molecule, requiring that VU591 assume a horseshoe
conformation to reach its binding site. Substitution of a
methyl group in BNBI with an oxygen atom in VU591
may support greater conformational flexibility and enable
VU591 to interact more intimately with its binding site.
Interestingly, Merck Research Laboratories recently dis-
closed an ROMK channel inhibitor that bears some struc-
tural similarities to VU591. Notably, the linker region of
this Merck compound contains a flexible piperazine group,
suggesting that it, too, may assume a horseshoe conforma-
tion in the pore to reach its binding site near N171 in the
ROMK channel pore. Garcia and colleagues reported that
N171 is also essential for block of ROMK by the Merck
inhibitor, (5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)pi-
perazin-1-yl)ethyl)isobenzofuran-1(3H)-one), termed com-
pound A (47).
Development of additional specific high-affinity inhibi-
tors targeting Kir channels would have value for both further
probe development and potential therapeutic applications.
In addition to HTS approaches being used to identify new
compounds, an attractive method for facilitating the dis-
covery of additional molecules is structure-based in silico
screening. Given a high-resolution crystal structure of the
target protein, in-silico predictions can accelerate the
screening procedure and aid in design and lead develop-Biophysical Journal 108(5) 1094–1103ment. This study demonstrates that the challenges of using
a comparative model in place of a crystal structure can be
overcome by using computational and experimental tech-
niques in concert to leverage the limited structural informa-
tion available for ROMK. This validated model is expected
to improve in quality as additional experimental data are
incorporated.SUPPORTING MATERIAL
Three figures and two tables are available at http://www.biophysj.org/
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